Non-executive director Dr Adam Hargreaves told last week's general meeting:
“Particular highlights include the development of a vertical market platform in fibrosis, which we are working on in collaboration with AstraZeneca; the progress towards clinical trials of the deodorant Optimer product with Unilever; and the undisclosed gene We have successfully produced an Optimer delivery conjugate for which we are planning preclinical testing with a pharmaceutical company.”
“Our increasing commercial traction has now enabled us to sign new contracts worth up to £471,000, which means the Group's funding sources remain strong and we are well positioned to develop all licensing opportunities over this long term. and potentially crystallize.”
The Board looks forward to updating shareholders on further developments. ”
